小细胞肺癌靶向治疗.pptxVIP

小细胞肺癌耐药机制及治疗新靶点;简介;耐药机制 ;ECM AKT/mTOR BCL-2/BCL-xl ;ATP-binding cassette transporters;Immunohistochemical Expression of MRP2 and Clinical Resistance to Platinum-based Chemotherapy in Small Cell Lung Cancer;;Response to chemotherapy according to immunostaining.;Response to chemotherapy according to immunostaining (CAVor platinum-based chemotherapy).;Multiple logistic regression analysis for chemotherapy response ;In platinum-based chemotherapy the expression of P-gp and MRP2 correlated with chemoresistance. This finding suggest that the immunohistochemical expression of MRP2 may be a useful predictor in the clinical resistance to cisplatin. ;Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer;Chemotherapeutic regiment;Association between expression of ABC transporter and response to chemotherapy and survival;;;小结; DNA excision repair gene;Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.;;Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer;ECM;;We have shown that ECM proteins can protect SCLC cells from chemotherapy-induced apoptosis. The mechanism underlying this process seems to be that 1-integrin-mediated adhesion of SCLC cells to ECM proteins promotes tyrosine phosphorylation, and this blocks chemotherapy-induced activation of the caspase pathway This mechanism is independent of chemotherapy-induced inhibition of topoisomerase II. ;The ECM-mediated protective effect could be blocked by eithera function-blocking antibody to 1 integrin or by a tyrosine kinase inhibitor. 目前尚无此方面临床实验． ;BCL-2;细胞试验提示BCL-2反义寡核苷酸可减少SCLC活性，与化疗结合可产生协同作用。 Phase I试验应用BCL-2反义寡核苷酸与carboplatin and etoposide联合缓解率有一定提高。